Search Results - "Shimura, Yuji"

Insights into very elderly multiple myeloma treatment from Kansai Myeloma Forum.

Authors: Okayama, Yusuke Takakuwa, Teruhito Shimura, Yuji et al.

Source: Hematology. Dec2025, Vol. 30 Issue 1, p1-10. 10p.

Multistep molecular trajectory of monocytic myeloid-derived suppressor cell induction by diffuse large B-cell lymphoma cells.

Authors: Inoue, Yu Shimura, Yuji Niiyama-Uchibori, Yui et al.

Source: Biochemical & Biophysical Research Communications. Mar2026, Vol. 804, pN.PAG-N.PAG. 1p.

Tumour‐derived exosomes promote the induction of monocytic myeloid‐derived suppressor cells from peripheral blood mononuclear cells by delivering miR‐106a‐5p and miR‐146a‐5p in multiple myeloma.

Authors: Mizuhara, Kentaro Shimura, Yuji Tsukamoto, Taku et al.

Source: British Journal of Haematology. Nov2023, Vol. 203 Issue 3, p426-438. 13p.

Lenalidomide and pomalidomide potently interfere with induction of myeloid‐derived suppressor cells in multiple myeloma.

Authors: Kuwahara‐Ota, Saeko Shimura, Yuji Steinebach, Christian et al.

Source: British Journal of Haematology. Dec2020, Vol. 191 Issue 5, p784-795. 12p.

Identification of non‐neutralizing anti‐factor X autoantibodies in three Japanese cases of autoimmune acquired factor X deficiency.

Authors: Souri, Masayoshi Osaki, Tsukasa Shimura, Yuji et al.

Source: Haemophilia. Mar2023, Vol. 29 Issue 2, p555-563. 9p. 1 Diagram, 2 Charts, 3 Graphs.

Primary intraocular natural killer-cell lymphoma successfully treated using a multidisciplinary strategy.

Authors: Takimoto-Shimomura, Tomoko Shimura, Yuji Nagata, Kenji et al.

Source: Annals of Hematology. Nov2019, Vol. 98 Issue 11, p2617-2619. 3p.

Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study.

Authors: Fujino, Takahiro Okamoto, Haruya Nishiyama, Daichi et al.

Source: Leukemia & Lymphoma. Aug2025, Vol. 66 Issue 8, p1425-1436. 12p.

Phosphorylation status and prognostic impacts of RSK2, PDPK1, and AKT in malignant lymphoma.

Authors: Onishi, Akio Miyagawa-Hayashino, Aya Okamoto, Haruya et al.

Source: Leukemia & Lymphoma. Aug2025, Vol. 66 Issue 8, p1413-1424. 12p.

This result is not displayed to guests.
Login for full access.

Non‐infectious fever defines a subgroup of patients with poorer survival outcomes in high‐risk myelodysplastic syndrome.

Authors: Nakamura, Takahisa Okamoto, Haruya Maekura, Chika et al.

Source: British Journal of Haematology. Jul2026, Vol. 209 Issue 1, p344-348. 5p.

Serine‐227 in the N‐terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.

Authors: Matsumura‐Kimoto, Yayoi Tsukamoto, Taku Shimura, Yuji et al.

Source: Cancer Medicine. Jul2020, Vol. 9 Issue 14, p5185-5199. 15p.

Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin.

Authors: Shimazu, Yutaka Kanda, Junya Kosugi, Satoru et al.

Source: Scientific Reports. 3/29/2023, Vol. 13 Issue 1, p1-12. 12p.

Watchful waiting is an acceptable treatment option for asymptomatic primary ocular adnexal mucosa‐associated lymphoid tissue lymphoma: A retrospective study.

Authors: Mizuhara, Kentaro Kobayashi, Tsutomu Nakao, Mitsushige et al.

Source: Cancer Medicine. Feb2023, Vol. 12 Issue 3, p3134-3144. 11p.

Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma.

Authors: Muramatsu, Ayako Kobayashi, Tsutomu Kawaji-Kanayama, Yuka et al.

Source: Leukemia & Lymphoma. Jul2022, Vol. 63 Issue 7, p1678-1685. 8p.

The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma.

Authors: Isa, Reiko Horinaka, Mano Tsukamoto, Taku et al.

Source: International Journal of Molecular Sciences. Mar2022, Vol. 23 Issue 6, p2919-2919. 18p.

The real-world efficacy and safety of frontline therapy of obinutuzumab plus bendamustine for untreated high-tumor-burden follicular lymphoma.

Authors: Nagata, Hiroaki Tsukamoto, Taku Kobayashi, Tsutomu et al.

Source: International Journal of Clinical Oncology. Mar2025, Vol. 30 Issue 3, p593-603. 11p.

The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients.

Authors: Shimazu, Yutaka Kanda, Junya Takakuwa, Teruhito et al.

Source: Annals of Hematology. Dec2024, Vol. 103 Issue 12, p5639-5649. 11p.

Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study.

Authors: Nakamura, Naokazu Arima, Nobuyoshi Takakuwa, Teruhito et al.

Source: Annals of Hematology. Dec2024, Vol. 103 Issue 12, p5681-5690. 10p.

Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis.

Authors: Takakuwa, Teruhito Yamamura, Ryosuke Ohta, Kensuke et al.

Source: European Journal of Haematology. Apr2021, Vol. 106 Issue 4, p555-562. 8p.

Mantle cell lymphoma with EBV‐positive Hodgkin and Reed–Sternberg‐like cells in a patient after autologous PBSCT: Phenotypically distinct but genetically related tumors.

Authors: Kanai, Risa Miyagawa‐Hayashino, Aya Shishido‐Hara, Yukiko et al.

Source: Pathology International. Jan2021, Vol. 71 Issue 1, p96-101. 6p.